MedPath

Acamprosate Calcium

These highlights do not include all the information needed to use ACAMPROSATE CALCIUM DELAYED-RELEASE TABLETS safely and effectively. See full prescribing information for ACAMPROSATE CALCIUM DELAYED-RELEASE TABLETS. ACAMPROSATE CALCIUM delayed-release tablets, for oral use Initial U.S. Approval: 2004

Approved
Approval ID

94ef2a5c-cc2f-4e7f-b159-b2d38188d5b8

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Aug 26, 2025

Manufacturers
FDA

American Health Packaging

DUNS: 929561009

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

Acamprosate Calcium

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code60687-121
Application NumberANDA202229
Product Classification
M
Marketing Category
C73584
G
Generic Name
Acamprosate Calcium
Product Specifications
Route of AdministrationORAL
Effective DateAugust 26, 2025
FDA Product Classification

INGREDIENTS (11)

SILICON DIOXIDEInactive
Code: ETJ7Z6XBU4
Classification: IACT
METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE AInactive
Code: NX76LV5T8J
Classification: IACT
CROSPOVIDONEInactive
Code: 2S7830E561
Classification: IACT
MAGNESIUM STEARATEInactive
Code: 70097M6I30
Classification: IACT
MICROCRYSTALLINE CELLULOSEInactive
Code: OP1R32D61U
Classification: IACT
PROPYLENE GLYCOLInactive
Code: 6DC9Q167V3
Classification: IACT
SODIUM STARCH GLYCOLATE TYPE A POTATOInactive
Code: 5856J3G2A2
Classification: IACT
TALCInactive
Code: 7SEV7J4R1U
Classification: IACT
MAGNESIUM SILICATEInactive
Code: 9B9691B2N9
Classification: IACT
ACAMPROSATE CALCIUMActive
Quantity: 333 mg in 1 1
Code: 59375N1D0U
Classification: ACTIB
POVIDONE, UNSPECIFIEDInactive
Code: FZ989GH94E
Classification: IACT

Drug Labeling Information

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

LOINC: 51945-4Updated: 4/30/2020

Package/Label Display Panel – Blister – 333 mg

333 mg Acamprosate Calcium DR Tablet Blister

Acamprosate
Calcium
Delayed-Release
Tablet

333 mg

DESCRIPTION SECTION

LOINC: 34089-3Updated: 4/30/2020

11 DESCRIPTION

Acamprosate calcium delayed-release tablets are supplied as an enteric-coated tablet for oral administration. Acamprosate calcium, USP is a synthetic compound with a chemical structure similar to that of the endogenous amino acid homotaurine, which is a structural analogue of the amino acid neurotransmitter γ-aminobutyric acid and the amino acid neuromodulator taurine. Its chemical name is calcium bis [3-(acetylamino) propane-1-sulfonate]. Its chemical formula is C 10H 20CaN 2O 8S 2 and molecular weight is 400.5 g/mol. Its structural formula is:

Acamprosate Calcium Structural Formula

Acamprosate calcium, USP is a white to almost white powder, odorless or nearly odorless powder. It is freely soluble in water and practically insoluble in alcohol and methylene chloride.

Each acamprosate calcium delayed-release tablet contains acamprosate calcium USP, 333 mg, equivalent to 300 mg of acamprosate. Inactive ingredients in acamprosate calcium delayed-release tablets include: colloidal silicon dioxide, crospovidone, methacrylic acid copolymer dispersion, magnesium silicate, magnesium stearate, microcrystalline cellulose, polyvinyl pyrollidone, propylene glycol, sodium starch glycolate, and talc. Sulfites were used in the synthesis of the drug substance and traces of residual sulfites may be present in the drug product.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

Acamprosate Calcium - FDA Drug Approval Details